BCL2 and Alzheimer disease: The mRNA expression of these parameters reverted to baseline in the AD + PhM + COMB group, exhibiting a considerable drop in Bax and an elevation in Bcl2 mRNA expression of 81% and 6.9-fold, respectively, in contrast to the AD group.